We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Ascentage Pharma (6855.HK) today announced that it has released the latest clinical data of its novel Bcl-2 selective inhibitor, lisaftoclax , in patients with relapsed/refractory (R/R) multiple myeloma (MM) or immunoglobulin light-chain (AL) amyloidosis.